Gerresheimer Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Gerresheimer sono diminuiti a un tasso medio annuo di -23.5%, mentre il settore Life Sciences ha visto gli utili diminuire a un tasso medio annuo di 4.5%. I ricavi sono cresciuti crescere a un tasso medio annuo di 9.8%.
Informazioni chiave
-23.51%
Tasso di crescita degli utili
-24.65%
Tasso di crescita dell'EPS
| Life Sciences Crescita del settore | 26.83% |
| Tasso di crescita dei ricavi | 9.83% |
| Rendimento del capitale proprio | -28.79% |
| Margine netto | -13.80% |
| Prossimo aggiornamento sugli utili | 15 Oct 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Jul 31
GXI: Reporting Delays And Accounting Concerns Will Restrain Confidence Despite China Expansion
Analysts have lifted their price target for Gerresheimer to about €25.26 from about €23.37, reflecting updated assumptions on future P/E levels after recent rating changes that cited valuation, delayed results and company specific overhangs. Analyst Commentary Recent research on Gerresheimer shows a mix of cautious and more constructive views, with several firms revisiting their ratings and price targets.Aggiornamento narrativa • Jun 16
GXI: Reporting Delays Accounting Scrutiny And Bormioli Overhang Will Cap Near Term Confidence
Gerresheimer's updated analyst price target has come down to €26.80 from €34.10. Analysts point to delayed results, accounting concerns and ongoing overhangs around Bormioli as key reasons for the reset.Aggiornamento narrativa • Jun 01
GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence
Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.
Aggiornamento narrativa • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
Aggiornamento narrativa • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Aggiornamento narrativa • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Aggiornamento narrativa • Mar 22
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Aggiornamento narrativa • Mar 07
GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.Aggiornamento narrativa • Feb 21
GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Articolo di analisi • Feb 10
Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Gerresheimer AG's ( ETR:GXI ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now compared...Aggiornamento narrativa • Feb 06
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).Aggiornamento narrativa • Jan 23
GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.Aggiornamento narrativa • Jan 09
GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.Aggiornamento narrativa • Dec 25
GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.Aggiornamento narrativa • Dec 11
GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.Articolo di analisi • Nov 30
These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Nov 27
GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.Aggiornamento narrativa • Nov 10
GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Articolo di analisi • Nov 02
Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
To the annoyance of some shareholders, Gerresheimer AG ( ETR:GXI ) shares are down a considerable 27% in the last...Aggiornamento narrativa • Oct 27
Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.Aggiornamento narrativa • Oct 13
New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.Aggiornamento narrativa • Sep 23
New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Articolo di analisi • Sep 18
Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Articolo di analisi • Jul 31
Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jun 18
Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Unfortunately for some shareholders, the Gerresheimer AG ( ETR:GXI ) share price has dived 28% in the last thirty days...Articolo di analisi • May 30
Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
Key Insights Gerresheimer's Annual General Meeting to take place on 5th of June Salary of €1.15m is part of CEO Dietmar...Articolo di analisi • May 29
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) will pay a dividend of €1.25 on the 10th of June. Based on this payment, the dividend yield...Articolo di analisi • May 14
Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
Gerresheimer AG ( ETR:GXI ), is not the largest company out there, but it led the XTRA gainers with a relatively large...Articolo di analisi • Apr 24
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend of €1.25 per share on the 10th of June. Based on...Articolo di analisi • Apr 19
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Gerresheimer AG's ( ETR:GXI ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Articolo di analisi • Apr 11
It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Gerresheimer AG ( ETR:GXI ) shares have had a horrible month, losing 32% after a relatively good period beforehand. The...Articolo di analisi • Apr 10
Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Gerresheimer AG's ( ETR:GXI ) investors are due to receive a payment of €1.25 per share on 10th of June. This means the...Articolo di analisi • Mar 05
Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
The board of Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend on the 10th of June, with investors...Articolo di analisi • Feb 25
Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Gerresheimer AG ( ETR:GXI ) shareholders would be excited to see that the share price has had a great month, posting a...
Nuova narrativa • Feb 09
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Articolo di analisi • Jan 12
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Gerresheimer guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Nov 25 | 2,321 | -320 | 439 | 22 |
| 31 Aug 25 | 2,250 | 23 | 415 | 22 |
| 31 May 25 | 2,188 | 63 | 409 | 21 |
| 28 Feb 25 | 2,090 | 79 | 397 | 23 |
| 30 Nov 24 | 1,991 | 82 | 387 | 24 |
| 31 Aug 24 | 2,012 | 114 | 368 | 19 |
| 31 May 24 | 2,002 | 115 | 368 | 15 |
| 29 Feb 24 | 1,999 | 117 | 372 | 13 |
| 30 Nov 23 | 1,990 | 116 | 373 | 16 |
| 31 Aug 23 | 1,974 | 107 | 380 | 19 |
| 31 May 23 | 1,959 | 107 | 378 | 23 |
| 28 Feb 23 | 1,904 | 97 | 368 | 26 |
| 30 Nov 22 | 1,817 | 96 | 351 | 22 |
| 31 Aug 22 | 1,725 | 91 | 336 | 17 |
| 31 May 22 | 1,634 | 82 | 314 | 15 |
| 28 Feb 22 | 1,566 | 85 | 298 | 12 |
| 30 Nov 21 | 1,498 | 84 | 285 | 10 |
| 31 Aug 21 | 1,465 | 86 | 278 | 8 |
| 31 May 21 | 1,432 | 93 | 272 | 8 |
| 28 Feb 21 | 1,418 | 94 | 272 | 9 |
| 30 Nov 20 | 1,419 | 89 | 275 | 8 |
| 31 Aug 20 | 1,385 | -25 | 275 | 7 |
| 31 May 20 | 1,394 | -32 | 275 | 5 |
| 29 Feb 20 | 1,388 | -14 | 273 | 1 |
| 30 Nov 19 | 1,392 | 81 | 273 | 0 |
| 31 Aug 19 | 1,415 | 207 | 273 | 0 |
| 31 May 19 | 1,410 | 207 | 270 | 0 |
| 28 Feb 19 | 1,386 | 179 | 265 | 0 |
| 30 Nov 18 | 1,368 | 129 | 259 | 0 |
| 31 Aug 18 | 1,351 | 124 | 258 | 0 |
| 31 May 18 | 1,329 | 131 | 256 | 0 |
| 28 Feb 18 | 1,336 | 137 | 258 | 0 |
| 30 Nov 17 | 1,348 | 101 | 259 | 0 |
| 31 Aug 17 | 1,331 | 49 | 257 | 0 |
| 31 May 17 | 1,350 | 53 | 259 | 0 |
| 28 Feb 17 | 1,358 | 56 | 258 | 0 |
| 30 Nov 16 | 1,375 | 58 | 259 | 0 |
| 31 Aug 16 | 1,299 | 118 | 243 | 0 |
| 31 May 16 | 1,292 | 106 | 240 | 0 |
| 29 Feb 16 | 1,301 | 99 | 238 | 0 |
| 30 Nov 15 | 1,283 | 96 | 231 | 0 |
| 31 Aug 15 | 1,335 | 69 | 236 | 0 |
Guadagni di qualità: GXI al momento non è redditizia.
Margine di profitto in crescita: GXI al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: GXI non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 23.5% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di GXI nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: GXI non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( 11.5% ).
Rendimento del capitale proprio
ROE elevato: GXI ha un Return on Equity negativo ( -28.79% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 11:34 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2025/11/30 |
| Utili annuali | 2025/11/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Gerresheimer AG è coperta da 30 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gaurav Jain | Barclays |
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |